Frankfurt
02.01.26 | 08:22
0,464 Euro
+1,09 % +0,005
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.25 | Egetis Therapeutics AB: Egetis Therapeutics initiates New Drug Application in the USA for Emcitate (tiratricol) for MCT8 deficiency | 149 | GlobeNewswire (Europe) | Stockholm, Sweden, December 19, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the Company has initiated a rolling New Drug Application... ► Artikel lesen | |
| 10.12.25 | Egetis Therapeutics AB: Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate Across Central, Eastern, and Southeastern Europe | 86 | GlobeNewswire (Europe) | Stockholm, Sweden, December 10, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the Company, through its wholly-owned subsidiary Rare Thyroid... ► Artikel lesen | |
| 25.11.25 | Egetis-Aktie unter Druck: Positive Studiendaten können Kursverlust nach Q3-Zahlen nicht verhindern | 2 | Investing.com Deutsch | ||
| EGETIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.11.25 | Egetis Therapeutics AB: Interim report Q3 2025 | 120 | GlobeNewswire (Europe) | Egetis to commence a rolling NDA submission in December as granted by the FDA for Emcitate® (tiratricol)· Egetis received FDA Breakthrough Therapy Designation for Emcitate® (tiratricol) for... ► Artikel lesen | |
| 14.11.25 | Egetis Therapeutics AB: Egetis announces positive results from the ReTRIACt study of Emcitate (tiratricol) in MCT8 deficiency | 97 | GlobeNewswire (Europe) | Positive topline results demonstrate a statistically significant (p=0.034) difference in the rate of change in serum T3 in patients randomized to withdrawal (placebo) vs. in patients continuing therapy... ► Artikel lesen | |
| 23.10.25 | Egetis Therapeutics AB: Egetis granted a rolling NDA review by FDA for Emcitate (tiratricol) based on currently available clinical data | 168 | GlobeNewswire (Europe) | The outcomes of a successful pre-NDA meeting with the FDA are:
As agreed with the FDA, the rolling NDA submission will commence in December 2025, targeting a complete NDA submission in early 2026 and... ► Artikel lesen | |
| 02.10.25 | Egetis Therapeutics AB: Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares | 154 | GlobeNewswire (Europe) | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA... ► Artikel lesen | |
| 21.08.25 | Egetis Therapeutics: Aktie steigt nach Q2-Zahlen trotz verfehlter Umsatzprognose | 2 | Investing.com Deutsch | ||
| 21.08.25 | Egetis Therapeutics AB: Interim report Q2 2025 | 199 | GlobeNewswire (Europe) | Egetis reports progress towards US NDA submission for tiratricol· FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis... ► Artikel lesen | |
| 18.08.25 | Egetis Therapeutics AB: Egetis reports progress towards US NDA submission for tiratricol | 474 | GlobeNewswire (Europe) | FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis of the survival data set from the international real-world cohort study by... ► Artikel lesen | |
| 15.07.25 | Egetis Therapeutics AB: Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency | 306 | GlobeNewswire (Europe) | Stockholm, Sweden, July 15, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough... ► Artikel lesen | |
| 05.05.25 | Egetis Therapeutics AB: Egetis Confirms Launch of Emcitate in Germany | 467 | GlobeNewswire (Europe) | For investors and media only
Stockholm, Sweden, May 5, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), a pharmaceutical company dedicated to developing therapies... ► Artikel lesen | |
| 30.04.25 | Egetis Therapeutics AB: Interim report Q1 2025 | 179 | GlobeNewswire (Europe) | Egetis plans to launch Emcitate® in the first country, Germany, on May 1, 2025The European Commission approved Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency.In... ► Artikel lesen | |
| 26.02.25 | Egetis Therapeutics AB: Year-End Report January-December 2024 | 359 | GlobeNewswire (Europe) | European Commission has approved Egetis' Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency· Egetis expects to launch Emcitate in the first country, Germany... ► Artikel lesen | |
| 13.02.25 | Egetis Therapeutics AB: European Commission approves Egetis' Emcitate (tiratricol) as the first and only treatment for patients with MCT8 deficiency | 422 | GlobeNewswire (Europe) | Stockholm, Sweden, February 13, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol)... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANOFI | 82,73 | -0,36 % | dpa-AFX-Überblick: UNTERNEHMEN - Die wichtigsten Meldungen der Weihnachtswoche | BP verkauft Mehrheit an Schmierstoff-Produzent Castrol für 6 Milliarden Dollar LONDON - Der Ölkonzern BP verkauft die Mehrheit am Schmierstoff-Produzenten Castrol für 6 Milliarden Dollar an den US-Investor... ► Artikel lesen | |
| GSK | 21,020 | -0,10 % | Pfizer, GSK and other drugmakers eying U.S. price hikes for 350 medicines: report | ||
| ASTRAZENECA | 156,65 | -0,76 % | AstraZeneca PLC - Total Voting Rights | ||
| TILRAY BRANDS | 8,155 | +3,91 % | Cannabis-Aktien im Abverkauf: Böses Omen für 2026? Anleger in Alarmstimmung bei Tilray, Canopy, Aurora & Co. | © Foto: adobe.stock.comMit dem Börsenjahr 2025 geht für den Cannabis-Sektor einmal mehr ein Jahr voller Herausforderungen zu Ende. Das Vertrauen von Anlegern und Investoren ist noch nicht zurück. Der... ► Artikel lesen | |
| DERMAPHARM | 38,300 | -2,67 % | DERMAPHARM HOLDING SE kracht ab - jetzt wird's brutal spannend! | ||
| QUANTUM BIOPHARMA | 5,800 | -17,14 % | Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) | TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 14,300 | +2,88 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) | Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product of TNX-4800 (anti-Borrelia... ► Artikel lesen | |
| CASSAVA SCIENCES | 1,763 | -0,03 % | Cassava Sciences, Inc.: Cassava Announces Agreement to Settle Securities Class Action Litigation | AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for... ► Artikel lesen | |
| OPKO HEALTH | 1,118 | +1,58 % | OPKO Health, Inc.: OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results | MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,605 | +27,16 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| SOLIGENIX | 1,380 | +3,37 % | SOLIGENIX, INC.: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) | Study results support advancing SGX945 in this difficult-to-treat orphan disease
Results suggest potential durability of response for maintenance therapy
PRINCETON, N.J., Dec. 18... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,025 | 0,00 % | BETTERLIFE HLDG (06909): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | ||
| THERIVA BIOLOGICS | 0,227 | +8,10 % | Theriva Biologics, Inc.: Theriva Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | - EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 5,785 | +2,39 % | NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards | EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's... ► Artikel lesen | |
| BAYER | 37,970 | +2,59 % | SAP, Bayer, Rheinmetall - was ist noch drin? | Für 2026 treffen bei deutschen Aktien hohe Erwartungen auf hohe Bewertungen. Auf fallende Kurse setzen - sprich short gehen - bleibt aber kompliziert in Sachen Timing. Denn wer in den vergangenen 15... ► Artikel lesen |
EGETIS THERAPEUTICS AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +1,09 % bei einem Aktienkurs von 0,464 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EGETIS THERAPEUTICS AB finden Sie auf Wallstreet Online.